...
sonn-img

Sonnet Biotherapeutics Holdings Inc, Common Stock

SONN

NAQ

$1.78

-$0.13

(-6.81%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.66M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
93.11K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.66 L
$18.72 H
$1.78

About Sonnet Biotherapeutics Holdings Inc, Common Stock

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSONNSectorS&P500
1-Week Return-5.45%-3.13%-0.02%
1-Month Return-42.12%-4.8%1.48%
3-Month Return-70.72%-8.46%9.63%
6-Month Return-87.23%-2.88%13.17%
1-Year Return-83.52%6.92%31.56%
3-Year Return-99.85%4.63%30.19%
5-Year Return-99.99%42.11%93.4%
10-Year Return-100%103.49%198.28%

Financials

Dec '19Sep '20Sep '21Sep '22Sep '235YR TREND
Total Revenue40.61M-483.63K349.94K147.81K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":1.19,"profit":true},{"date":"2022-09-30","value":0.86,"profit":true},{"date":"2023-09-30","value":0.36,"profit":true}]
Cost of Revenue7.93M58.31K16.63M93.26K11.81M[{"date":"2019-12-31","value":47.69,"profit":true},{"date":"2020-09-30","value":0.35,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":0.56,"profit":true},{"date":"2023-09-30","value":71.02,"profit":true}]
Gross Profit32.68M(58.31K)(16.15M)256.69K(11.67M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-09-30","value":-0.18,"profit":false},{"date":"2021-09-30","value":-49.42,"profit":false},{"date":"2022-09-30","value":0.79,"profit":true},{"date":"2023-09-30","value":-35.7,"profit":false}]
Gross Margin80.47%-(3339.55%)73.35%(7893.43%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":-4150.24,"profit":false},{"date":"2022-09-30","value":91.16,"profit":true},{"date":"2023-09-30","value":-9809.6,"profit":false}]
Operating Expenses4.71M17.41M25.57M30.02M18.94M[{"date":"2019-12-31","value":15.68,"profit":true},{"date":"2020-09-30","value":58,"profit":true},{"date":"2021-09-30","value":85.18,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":63.09,"profit":true}]
Operating Income(4.71M)(24.24M)(25.09M)(29.67M)(18.79M)[{"date":"2019-12-31","value":-470833800,"profit":false},{"date":"2020-09-30","value":-2423777200,"profit":false},{"date":"2021-09-30","value":-2508743600,"profit":false},{"date":"2022-09-30","value":-2966935900,"profit":false},{"date":"2023-09-30","value":-1879261700,"profit":false}]
Total Non-Operating Income/Expense(325.75K)(6.67K)103.49K(52.48K)-[{"date":"2019-12-31","value":-314.76,"profit":false},{"date":"2020-09-30","value":-6.44,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-50.71,"profit":false},{"date":"2023-09-30","value":"-","profit":true}]
Pre-Tax Income(4.87M)(24.27M)(24.98M)(29.72M)(18.83M)[{"date":"2019-12-31","value":-487121100,"profit":false},{"date":"2020-09-30","value":-2426511500,"profit":false},{"date":"2021-09-30","value":-2498396100,"profit":false},{"date":"2022-09-30","value":-2972184100,"profit":false},{"date":"2023-09-30","value":-1883269400,"profit":false}]
Income Taxes162.87K6.80M22.03K52.48K40.08K[{"date":"2019-12-31","value":2.4,"profit":true},{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":0.32,"profit":true},{"date":"2022-09-30","value":0.77,"profit":true},{"date":"2023-09-30","value":0.59,"profit":true}]
Income After Taxes(5.03M)(31.06M)(25.01M)(29.77M)-[{"date":"2019-12-31","value":-503408400,"profit":false},{"date":"2020-09-30","value":-3106064000,"profit":false},{"date":"2021-09-30","value":-2500598700,"profit":false},{"date":"2022-09-30","value":-2977432300,"profit":false},{"date":"2023-09-30","value":"-","profit":true}]
Income From Continuous Operations(17.44M)(24.27M)(24.98M)(29.72M)(18.83M)[{"date":"2019-12-31","value":-1744335800,"profit":false},{"date":"2020-09-30","value":-2426511500,"profit":false},{"date":"2021-09-30","value":-2498396100,"profit":false},{"date":"2022-09-30","value":-2972184100,"profit":false},{"date":"2023-09-30","value":-1883269400,"profit":false}]
Income From Discontinued Operations(1.02M)----[{"date":"2019-12-31","value":-102167400,"profit":false},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Net Income(5.03M)(31.06M)(25.01M)(29.77M)(18.83M)[{"date":"2019-12-31","value":-503408400,"profit":false},{"date":"2020-09-30","value":-3106064000,"profit":false},{"date":"2021-09-30","value":-2500598700,"profit":false},{"date":"2022-09-30","value":-2977432300,"profit":false},{"date":"2023-09-30","value":-1883269400,"profit":false}]
EPS (Diluted)-(5.58)(3.43)(6.85)(3.36)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-09-30","value":-557.65,"profit":false},{"date":"2021-09-30","value":-343,"profit":false},{"date":"2022-09-30","value":-685,"profit":false},{"date":"2023-09-30","value":-336,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SONN
Cash Ratio 1.14
Current Ratio 1.65

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SONN
ROA (LTM) -96.93%
ROE (LTM) -264.57%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SONN
Debt Ratio Lower is generally better. Negative is bad. 0.55
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.45

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SONN
Trailing PE NM
Forward PE NM
P/S (TTM) 29.68
P/B 0.63
Price/FCF NM
EV/R 35.91
EV/Ebitda NM

FAQs

What is Sonnet Biotherapeutics Holdings Inc share price today?

Sonnet Biotherapeutics Holdings Inc (SONN) share price today is $1.78

Can Indians buy Sonnet Biotherapeutics Holdings Inc shares?

Yes, Indians can buy shares of Sonnet Biotherapeutics Holdings Inc (SONN) on Vested. To buy Sonnet Biotherapeutics Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SONN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sonnet Biotherapeutics Holdings Inc be purchased?

Yes, you can purchase fractional shares of Sonnet Biotherapeutics Holdings Inc (SONN) via the Vested app. You can start investing in Sonnet Biotherapeutics Holdings Inc (SONN) with a minimum investment of $1.

How to invest in Sonnet Biotherapeutics Holdings Inc shares from India?

You can invest in shares of Sonnet Biotherapeutics Holdings Inc (SONN) via Vested in three simple steps:

  • Click on Sign Up or Invest in SONN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sonnet Biotherapeutics Holdings Inc shares
What is Sonnet Biotherapeutics Holdings Inc 52-week high and low stock price?

The 52-week high price of Sonnet Biotherapeutics Holdings Inc (SONN) is $18.72. The 52-week low price of Sonnet Biotherapeutics Holdings Inc (SONN) is $1.66.

What is Sonnet Biotherapeutics Holdings Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sonnet Biotherapeutics Holdings Inc (SONN) is

What is Sonnet Biotherapeutics Holdings Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sonnet Biotherapeutics Holdings Inc (SONN) is 0.63

What is Sonnet Biotherapeutics Holdings Inc dividend yield?

The dividend yield of Sonnet Biotherapeutics Holdings Inc (SONN) is 0.00%

What is the Market Cap of Sonnet Biotherapeutics Holdings Inc?

The market capitalization of Sonnet Biotherapeutics Holdings Inc (SONN) is $1.66M

What is Sonnet Biotherapeutics Holdings Inc’s stock symbol?

The stock symbol (or ticker) of Sonnet Biotherapeutics Holdings Inc is SONN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top